社论：关于IV期非小细胞肺癌 - Suppr | 超能文献

文献检索
文档翻译
深度研究
学术资讯

Zotero 插件

邀请有礼
套餐&价格
历史记录

应用&插件

Zotero 插件浏览器插件 Mac 客户端 Windows 客户端微信小程序

定价

高级版会员购买积分包购买API积分包

服务

文献检索文档翻译深度研究 API 文档 MCP 服务

关于我们

关于 Suppr 公司介绍联系我们用户协议隐私条款

关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1

Editorial: in stage IV non-small cell lung cancer.社论：关于IV期非小细胞肺癌

Front Oncol. 2025 Mar 10;14:1517049. doi: 10.3389/fonc.2024.1517049. eCollection 2024.

2

Prognostic Implication of G12C Mutation in a Real-World -Mutated Stage IV NSCLC Cohort Treated With Immunotherapy in The Netherlands.荷兰接受免疫治疗的真实世界IV期非小细胞肺癌G12C突变队列中G12C突变的预后意义

JTO Clin Res Rep. 2023 Jun 29;4(9):100543. doi: 10.1016/j.jtocrr.2023.100543. eCollection 2023 Sep.

3

Complete response to nivolumab in Kirsten rat sarcoma virus oncogene KRAS-G12C mutant metastatic lung adenocarcinoma: a case report.转移性肺腺癌中 Kirsten 鼠肉瘤病毒致癌基因 KRAS-G12C 突变对纳武利尤单抗的完全应答：病例报告。

J Med Case Rep. 2022 Nov 3;16(1):420. doi: 10.1186/s13256-022-03593-3.

4

KRAS Inhibitors in Non-Small Cell Lung Cancer: A Review.非小细胞肺癌中的KRAS抑制剂：综述

Onco Targets Ther. 2024 Aug 24;17:683-695. doi: 10.2147/OTT.S473368. eCollection 2024.

5

Immunotherapy in advanced, G12C-mutant non-small-cell lung cancer: current strategies and future directions.晚期G12C突变型非小细胞肺癌的免疫治疗：当前策略与未来方向

Ther Adv Med Oncol. 2025 Mar 14;17:17588359251323985. doi: 10.1177/17588359251323985. eCollection 2025.

6

Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC).社论：索托拉西布获批成为首个针对 KRAS G12C 突变型晚期非小细胞肺癌（NSCLC）的靶向治疗药物。

Med Sci Monit. 2022 Nov 1;28:e938746. doi: 10.12659/MSM.938746.

7

Emerging Therapies in Kirsten Rat Sarcoma Virus (+) Non-Small-Cell Lung Cancer.Kirsten 大鼠肉瘤病毒（+）非小细胞肺癌的新兴疗法

Cancers (Basel). 2024 Apr 9;16(8):1447. doi: 10.3390/cancers16081447.

8

Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development-a narrative review.KRAS 突变型非小细胞肺癌的靶向治疗：从临床前研究到临床开发——一篇叙述性综述

Transl Lung Cancer Res. 2023 Feb 28;12(2):346-368. doi: 10.21037/tlcr-22-639. Epub 2023 Feb 20.

9

Activity and resistance to KRAS inhibitors in non-small cell lung cancer and colorectal cancer.非小细胞肺癌和结直肠癌中的 KRAS 抑制剂活性和耐药性。

Biochim Biophys Acta Rev Cancer. 2024 May;1879(3):189108. doi: 10.1016/j.bbcan.2024.189108. Epub 2024 May 8.

10

Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.索托拉西布：一种用于治疗KRAS G12C突变的非小细胞肺癌的药物。

Drugs Today (Barc). 2022 Apr;58(4):175-185. doi: 10.1358/dot.2022.58.4.3400573.

本文引用的文献

1

Prognostic Implication of G12C Mutation in a Real-World -Mutated Stage IV NSCLC Cohort Treated With Immunotherapy in The Netherlands.荷兰接受免疫治疗的真实世界IV期非小细胞肺癌G12C突变队列中G12C突变的预后意义

JTO Clin Res Rep. 2023 Jun 29;4(9):100543. doi: 10.1016/j.jtocrr.2023.100543. eCollection 2023 Sep.

2

Lung Cancer in Indonesia.印度尼西亚的肺癌

J Thorac Oncol. 2023 Sep;18(9):1134-1145. doi: 10.1016/j.jtho.2023.06.010.

3

Pan-KRAS inhibitor disables oncogenic signalling and tumour growth.泛 KRAS 抑制剂使致癌信号和肿瘤生长失活。

Nature. 2023 Jul;619(7968):160-166. doi: 10.1038/s41586-023-06123-3. Epub 2023 May 31.

4

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS mutation: a randomised, open-label, phase 3 trial.索托拉西布与多西他赛用于既往接受过治疗的KRAS突变非小细胞肺癌：一项随机、开放标签的3期试验。

Lancet. 2023 Mar 4;401(10378):733-746. doi: 10.1016/S0140-6736(23)00221-0. Epub 2023 Feb 7.

5

Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.非癌基因成瘾性转移性非小细胞肺癌：ESMO诊断、治疗及随访临床实践指南

Ann Oncol. 2023 Apr;34(4):358-376. doi: 10.1016/j.annonc.2022.12.013. Epub 2023 Jan 17.

6

Adagrasib in Non-Small-Cell Lung Cancer Harboring a Mutation.在携带有突变的非小细胞肺癌中使用阿达格拉西布。

N Engl J Med. 2022 Jul 14;387(2):120-131. doi: 10.1056/NEJMoa2204619. Epub 2022 Jun 3.

7

Sotorasib for Lung Cancers with p.G12C Mutation.索托拉西布治疗 p.G12C 突变型肺癌。

N Engl J Med. 2021 Jun 24;384(25):2371-2381. doi: 10.1056/NEJMoa2103695. Epub 2021 Jun 4.

8

Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy.KRAS突变状态对一线帕博利珠单抗单药治疗的IV期肺腺癌患者的预后影响

Lung Cancer. 2021 May;155:163-169. doi: 10.1016/j.lungcan.2021.04.001. Epub 2021 Apr 5.

9

Lung Cancer in the Netherlands.荷兰的肺癌

J Thorac Oncol. 2021 Mar;16(3):355-365. doi: 10.1016/j.jtho.2020.10.012.

10

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。

CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.

社论：关于IV期非小细胞肺癌 - Suppr | 超能文献

Editorial: in stage IV non-small cell lung cancer.

作者信息

Noordhof Anneloes L, Blum Torsten Gerriet, Hardavella Georgia, Hendriks Lizza E L, van Geffen Wouter H

机构信息

Department of Respiratory Medicine, Medical Center Leeuwarden, Leeuwarden, Netherlands.

Department of Pneumology, Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring, Berlin, Germany.

出版信息

Front Oncol. 2025 Mar 10;14:1517049. doi: 10.3389/fonc.2024.1517049. eCollection 2024.

DOI:10.3389/fonc.2024.1517049

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11930799/

Abstract

摘要